Clinical trial of CV 9202 in combination with afatinib in patients with advanced or metastatic epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2014
At a glance
- Drugs CV 9202 (Primary) ; Afatinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Sep 2014 New trial record